💎 癌症為什麼難治？其中一大原因在於，癌細胞會利用一切可能的機制，逃脫化療藥物和標靶治療的追殺。這也正是為什麼很多癌症治療後，身體會對藥物產生抗藥性，最終導致治療失敗和腫瘤復發。因此，發掘新的抗藥及轉移機制一直是全人類的目標！本次TTBA年會邀請到德州大學聖安東尼奧健康醫學中心Mays癌症中心的副院長黃慧明博士，分享他如何透過 single cell-based techniques 進行攝護腺癌轉移的研究。透過黃博士的研究成果，希望讓各位會員更了解最新的轉移機制與標靶藥物策略！

#美國教授圖鑑

💎About 黃慧明博士 Tim Hui-Ming Huang, Ph.D.

現任

Department of Molecular Medicine 系主任, UT Health Science Center at San Antonio

Mays Cancer Center 副院長, UT Health San Antonio MD Anderson Cancer Center

Alice P. McDermott President’s Distinguished University Chair

Minnie Tomerlin Voelcker Distinguished University Chair

PI of NCI’s U54 Center for Cancer Systems Biology 

曾任職 University of Missouri - Columbia (1991-2003); The Ohio State University (2003-2011); Fellow of American Association for the Advancement of Science (2006). 

💎Abstract:  

Cell-cell fusion is a critical cellular event for development and differentiation. Emerging evidence has shown that fusion of normal cells and tumor cells can lead to cancer progression. In a recent study, we have identified a unique population of macrophages harboring prostate cancer cells' characteristics. These hybrid cells are like a Trojan Horse, unnoticeably evading immune surveillance and intruding into distant organs. Using a single cell-based technique, we are able to detect hybrid cells in blood samples of patients undergoing anti-hormone therapies. This non-invasive approach represents a brand-new option of liquid biopsy for predicting patients’ treatment outcomes.

💎Biography: 

Dr. Huang received his bachelor’s degree in biology from Tunghai University, Taiwan in 1980 and his Ph.D. degree in genetics from the University of California at Davis in 1989.  From 1989 to 1991, he was a clinical cytogenetics fellow at Baylor College of Medicine, Houston.  He was a faculty member at the University of Missouri - Columbia (1991-2003) and at the Ohio State University (2003-2011).  In 2006, Dr. Huang was named as a Fellow of the American Association for the Advancement of Science. He has served as the PI of NCI’s U54 Center for Cancer Systems Biology for the past 18 years. Presently, he is Alice P. McDermott Distinguished University Professor and Chairman in the Department of Molecular Medicine and Deputy Director of Mays Cancer Center at the University of Texas Health Science Center - San Antonio. His research team has developed novel technologies to characterize single-cell genomic, transcriptomic, and proteomic patterns of tumor cell subpopulations. Throughout these studies, he has authored or co-authored ~327 peer-reviewed papers and book chapters and has mentored 110 pre- and post-doctoral trainees and junior faculty. 

💎工程技術在生醫產業應用中，如何生成精準的液滴體積—微升(μL)小至皮升(pL)—是一門重要的應用學問。電控微流體(Electromicrofluidics, EMF)是高度精密又靈活控制的液滴系統，范士岡教授將介紹數種EMF技術，透過調節局部電場來控制液滴與水膠，達成移動液體的自動化，應用於醫學檢測以及異質(heterogeneous)生物3D/4D列印—例如仿生肝臟與列印肌肉，並且范教授將更進一步討論更多電控數位微流體的潛在商業利用價值。

#美國教授圖鑑

💎About 范士岡博士 Shih-Kang Scott Fan, Ph.D.

現任堪薩斯州立大學 機械與核子工程系教授

英國皇家化學學會會士

電控微流體專家

新創公司創辦人

💎Abstract:  

Generation and actuation of droplets with a wide range of volume from pl to μl are of great interest and significance in biomedical applications. In this talk, I will introduce several electromicrofluidics techniques to manipulate droplets of various fluids and hydrogels by programmable local electric fields on an electrode array without using microchannels nor micropumps. The agile actuations of droplets with appropriate volume and ingredients enable the automation of bioassays and enhance the heterogeneity of bioprinting. The capability and potential of digital assays for single entities using electromicrofluidics will be briefly discussed.

💎Biography: 

Shih-Kang Scott Fan is a professor of Mechanical and Nuclear Engineering at Kansas State University. He received his B.S. degree from National Central University, Taiwan in 1996, and M.S. and Ph.D. degrees from the University of California, Los Angeles (UCLA) in 2001 and 2003, respectively. In 2004 he joined the faculty of National Chiao Tung University, Taiwan as an assistant professor and was promoted to an associate professor in the Institute of Nanotechnology and the Department of Materials Science. From 2012-2019 he was with the Department of Mechanical Engineering and the Center for Biotechnology at National Taiwan University, Taiwan as an associate professor, professor and distinguished professor.

💎在職涯發展的路途上，不論是誰都有走得有些迷惘不安的時期。能在一開始就確定自身感興趣的領域與工作的人少之又少，絕大多數人都是在勇於嘗試與體驗後，才慢慢摸索出有熱忱的事物並找到最適合自己的工作類型。而這樣的過程多多少少都必需經歷一些轉換與適應期，可能是轉換研究領域，也可能是從熟悉的學界轉換到風氣與步調截然不同的業界。如何進行職涯轉換的準備、如何走過轉換的陣痛期想必都是大家最想知道的問題。本次年會我們請來兩位有相關經歷的講者，其中林鋐穎博士將和我們分享身為具有農業背景的生物資訊博士，他是如何轉換領域進入業界，進行癌症相關的生醫資訊研究。而吳爵宇博士則會和我們聊聊作為一個微流體工程師，當初在學界的研究經歷如何幫助他更順利在業界進行將微流體設備應用於生醫器材的相關研發工作。對於想突破舒適圈、挑戰新事物，進而取得更高職涯成就的你，請不要錯過本次的講座！

💎關於 Hung-Ying Lin, Ph.D. 林鋐穎博士

於 Bristol Myers Squibb (BMS) 擔任 Senior Scientist Translational Bioinformatics

曾於 Sema4 擔任 Bioinformatic scientist

生資魔術師

愛荷華州立大學基因體學博士

💎Abstract:  Sequencing technology has developed dramatically and brought a paradigm shift in biological areas from plant, animal, and medical genomic research. The urgent demands of analyzing and interpreting tons of data leads to the fast-evolving science of bioinformatics. What would be the required skills to be a modern bioinformatician? What are the gaps between school and the workforce? How did a plant breeding student change careers from corn to immuno-oncology fields?  Let's embark on a challenging but rewarding adventure from a "bioinformatician" to "bioinformagician".

💎Biography: Dr. Hung-Ying Lin is a Senior Scientist at Bristol Myers Squibb (BMS), Translational Bioinformatics. In this position, he provides statistical and computational tools for various genomic datasets in clinical trials and research projects. He has made several production level pipelines for oncology data from the assembly, alignment, visualization, single-nucleotide variant, fusion, splicing calling, visualizations, single-cell RNA sequencing, TCR-Seq and Copy Number Variation. Before joining BMS, Dr. Lin was a Bioinformatic scientist at a molecular diagnosis company, Sema4, where he developed an NYDOH-approved oncology whole-exome sequencing pipeline running on AWS. In a nutshell, his specialty covers cloud computing, oncology, computational biology, and genetics.

💎關於 Chueh-Yu (Jerry) Wu, Ph.D. 吳爵宇博士

於 Pattern Bioscience 擔任 Scientist

曾任職於Azure Biosystems

微流體專家

加州大學洛杉磯分校機械工程博士

💎Abstract:  Microfluidics plays an important role in advancing biotechnology and provides unique platforms for several applications, including point-of-care diagnosis and tissue engineering. After decades of evolution, there is a need to fill the gap between academic research and commercialized product to move the field forward. Understanding the bridge across the difference between academic research and commercialization can improve the development on both sides: the research of Microfluidic devices and systems with great functionality can be aligned toward the direction with high potential for real-world applications while the product development based on the concept of micro-scale reactions can be highly benefited by related fundamental knowledge. Let’s share and discuss the corresponding experience gained in the early-stage career.

💎Biography: Chueh-Yu (Jerry) Wu received his Ph.D. degree from the Department of Mechanical Engineering at UCLA. His research focused on inertial-microfluidics-based manufacturing technology of 3D complex microparticles/micro hydrogel and particle-templated droplet generation.  He joined Azure Biosystems to develop the imager and laser scanner for western blotting assay and also work on launching an optical-fiber-based qPCR machine for multiplex reactions. Now he is working at Pattern Bioscience to develop the first digital bacteria culture platform to accelerate the diagnosis speed of bacterial infection and solve the global healthcare issue. He is currently contributing to consumable development and system integration. 

💎本次會議的第三場Keynote，我們很榮幸邀請到曾國富博士、林振銘博士來分享他們在業界的就職經驗。曾博士將和我們聊聊他在精準醫療產業的一家新創公司—Aetio Biotherapy Inc. 的工作經驗，包括他們的藥物研發策略，以及在新創公司工作的優缺點。林博士則會和我們分享何謂生技代工業（CDMO），包括介紹CDMO公司中不同的職位與他們的工作內容，其中將特別聚焦於他所任職的部門—Process Development。希望透過兩位業界前輩的經驗分享，能幫助我們更順利地規劃自己的未來！

💎關於 Kuo-Fu Tseng, Ph.D. 曾國富博士

-於Aetio Biotherapy Inc. 擔任Chief Scientific Officer

-奧瑞岡州立大學細胞與分子生物學博士

💎關於 Chen-Ming (Eric) Lin , Ph.D. 林振銘博士

-於 Fujifilm Diosynth Biotechnologies擔任Senior Scientist

-貝勒大學化學博士

【Kuo-Fu Tseng, Ph.D. 】

💎Abstract: Therapeutic antibodies had been approved and widely used in cancer treatments for decades. These antibodies are designed to target tumor specific antigens and trigger immune responses for killing cancer cells. However, On-target off-tumor binding of antibodies often results in systematic toxicities after administration. Aetio Biotherapy Inc. is a startup company focusing on developing novel platforms or strategies to maximize the efficacy and minimize the toxicity in cancer immunotherapy, including antibody and cytokine Prodrugs. It is an honor to have this opportunity to share my experience working in this startup company.  

💎Biography: Dr. Kuo-Fu Tseng received his bachelor’s degree in Life Science from Fu-Jen University in 2002 and his Ph.D. degree in Cellular and Molecular Biology from Oregon State University in 2014. After his postdoc training in the Department of Physics in Oregon State University from 2015 to 2019, he joined Aetio Biotherapy Inc. and started his career journey in the Biotech industry. 

【Chen-Ming (Eric) Lin , Ph.D.】

💎Abstract:  Pharmaceutical CDMO (Contract Development and Manufacturing Organization) is one of the biomedical industry branches, and is focusing on cGMP manufacturing process of client’s project. In this talk, we will introduce the role of CDMO in the biomedical industry and give a general overview of scientific jobs in CDMO, with a specific focus on PD (Process Development) department positions including assistant, associate, senior and principal scientists. We will also discuss the CDMO career prospectus which will provide a good road map for your own career development.

💎Biography: Dr. Lin is currently a Senior Scientist in Upstream Process Development, FUJIFILM Diosynth Biotechnologies, College Station, Texas. He is a bioorganic chemist in rational design, synthesis characterization and biological evaluation in oncology. Dr. Lin received his PhD degree in Chemistry from Baylor University in 2015 and conducted his postdoctoral training in the Department of Chemistry, Texas A&M University. He majored in Pharmacy for his undergraduate degree in National Taiwan University and was a pharmacist in Taiwan.